The roller-coaster ride for eFFECTOR Therapeutics, Inc., symbolized by the stock code EFTR, took a sharp nosedive by 82% on April 4th. The catalyst behind this free fall was the lackluster results unveiled from the crucial analysis of its mid-stage trial pertaining to non-small cell lung cancer (NSCLC). Consequently, the curtains were drawn on the tomivosertib development program for first-line NSCLC treatment.
This randomized phase II study, dubbed KICKSTART, was designed to assess the safety and efficacy of tomivosertib, the company’s experimental drug, alongside Merck‘s Keytruda (pembrolizumab), against a placebo in treating NSCLC patients with PD-L1 levels ≥50%.
As the dust settled on the evaluation of 36 pivotal incidents in the mid-phase research, the stated PFS – progression-free survival – p value fell short, coming in at 0.21. This number failed to meet the predefined standard of p≤0.2. While the overall survivability data was yet to mature, it displayed no discernible favoritism towards the tomivosertib/Keytruda combination. Additionally, severe treatment-related adverse events were recorded in 67% of patients on the tomivosertib- Keytruda combination, significantly higher than those in the placebo group.
Despite the grim results, a flicker of hope emerged with a favorable hazard ratio of 0.62 for PFS inclined towards the tomivosertib/Keytruda regimen. The median PFS, standing at 13 weeks in the tomivosertib group, marginally outperformed the 11.7 weeks seen in the placebo cohort.
Since the start of the year, eFFECTOR Therapeutics has incurred a staggering 74.7% drop in its share value, contrasting sharply with the broader medical, biomedical, and genetics industry‘s mild 3.7% dip.
Image Source: Zacks Investment Research
In the aftermath of shelving the tomivosertib venture, EFTR announced a strategic pivot towards its clinical-stage asset, zotatifin. This compound is undergoing phase IIa trials in different combinations – as a standalone therapy, with fulvestrant, and in conjunction with fulvestrant plus abemaciclib – for estrogen receptor-positive breast cancer treatment.
Unlike the doomed tomivosertib, eFFECTOR Therapeutics’ zotatifin touts a distinctive mode of operation, setting it apart in the drug development landscape. The company is now gearing up to commence a registration trial for zotatifin in breast cancer later in 2024.
Anticipated in the latter half of 2024 is further data from the ongoing phase IIa study, pinpointing the recommended dose for zotatifin in combination with fulvestrant and abemaciclib. Despite the setback in NSCLC, the separate research study examining tomivosertib’s efficacy in acute myeloid leukemia (AML) stands uninterrupted. eFFECTOR Therapeutics clarified that the rationale behind testing tomivosertib in AML is distinctly separate from its NSCLC rationale, hence, unaffected by the NSCLC study failure.
Presently, Merck enjoys a dominant market position with Keytruda, its beacon of hope in frontline metastatic NSCLC therapy. Keytruda, a leading anti-PD-1 therapy, is Merck’s crown jewel in oncology therapeutics, contributing to nearly half of the pharmaceutical giant’s sales in 2023.
Merck’s Keytruda boasts approvals across eight indications for early-stage cancers in the US. With a robust expansion strategy, Keytruda continues to carve its path into new markets and indications, thus fortifying Merck’s foothold in the oncology segment.
The Performance of eFFECTOR Therapeutics, Inc. in Numbers
eFFECTOR Therapeutics, Inc. price-consensus-chart | eFFECTOR Therapeutics, Inc. Quote
Zacks Rank and Other Stocks Worth Considering
eFFECTOR Therapeutics presently holds a Zacks Rank #2 (Buy).
Looking beyond eFFECTOR, other standout performers in the drug/biotech sphere include ADMA Biologics and FibroGen. ADMA currently shines with a Zacks Rank #1 (Strong Buy) while FGEN holds a Zacks Rank #2 at the moment. For a comprehensive list of today’s Zacks #1 Rank stocks, be sure to check out the complete list here.
Over the past month, the Zacks Consensus Estimate for ADMA Biologics’ 2024 earnings per share (EPS) showed no movement, remaining stable at 30 cents. During the same timeframe, the projections for ADMA’s 2025 EPS stood firm at 50 cents. Year-to-date, ADMA shares have surged by 38.9%.
ADMA outperformed market expectations in three of the last four quarters and met them in one, leading to an average earnings beat of 85%.
Over the past month, FibroGen’s 2024 estimated loss per share stayed constant at $1.09. Concurrently, the 2025 forecast for losses per share also held steady at 6 cents. Impressively, FGEN shares soared by 78.3% year-to-date.
FGEN managed to surpass estimates in two of the last four quarters, albeit missing the mark in the remaining two, resulting in an average negative surprise of 2.26%.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Find out more from Zacks Investment Research
Disclaimer: The opinions and views expressed in this article belong solely to the author and not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
